Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Invested Capital (2019 - 2025)

Lyell Immunopharma (LYEL) has disclosed Invested Capital for 7 consecutive years, with $248.2 million as the latest value for Q4 2025.

  • Quarterly Invested Capital fell 35.17% to $248.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $248.2 million through Dec 2025, down 35.17% year-over-year, with the annual reading at $248.2 million for FY2025, 35.17% down from the prior year.
  • Invested Capital hit $248.2 million in Q4 2025 for Lyell Immunopharma, down from $329.1 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $1.0 billion in Q2 2021 to a low of -$334.0 million in Q1 2021.
  • Historically, Invested Capital has averaged $608.8 million across 5 years, with a median of $676.3 million in 2023.
  • Biggest five-year swings in Invested Capital: soared 525.62% in 2021 and later crashed 47.23% in 2025.
  • Year by year, Invested Capital stood at $929.8 million in 2021, then dropped by 10.38% to $833.3 million in 2022, then dropped by 21.4% to $655.0 million in 2023, then tumbled by 41.55% to $382.8 million in 2024, then crashed by 35.17% to $248.2 million in 2025.
  • Business Quant data shows Invested Capital for LYEL at $248.2 million in Q4 2025, $329.1 million in Q3 2025, and $298.9 million in Q2 2025.